Novavax, Inc.
NASDAQ:NVAXBiotechnology
-$0.18 today
- Market cap
- $1.31B
- Beta
- 2.41
- P/E (TTM)
- -17.3
- EPS (TTM)
- -$0.54
Volume 4.24M
Average 4.58M
NVAX Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Novavax, Inc.NASDAQ: NVAX
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables growth accelerates
Q1 FY2026 accounts receivables of $86.24M rose 16.8% year over year, ahead of the -44.3% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -37.4% a year.
Context
- Accounts receivables amounted to 5.4% of revenue in FY2025, down 46.5 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +16.8% holds above the trailing-twelve-month pace of -44.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 61.04M USD
- Year-over-year change
- -82.8%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 61.04M | -82.8% |
| FY2024 | 2024-12-31 | 354.09M | +229.0% |
| FY2023 | 2023-12-31 | (274.44M) | -210.1% |
| FY2022 | 2022-12-31 | 249.17M | +229.6% |
| FY2021 | 2021-12-31 | (192.27M) | — |
Accounts Receivables vs competitors
How NVAX compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -44.3% is the 5th highest of 7, against a peer median of +53.3%.
- Accounts receivables amounts to 12.3% of revenue for NVAX, versus a peer median of 12.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €1.89B EUR | +210.6% | -38.0% | 71.6% | |
| LTM Sep 2026 | $325M USD | -164.6% | -55.7% | 12.9% | |
| LTM Mar 2026 | $73.42M USD | -44.3% | -37.4% | 12.3% | |
| LTM Mar 2026 | $59.9M USD | +225.6% | -40.0% | 8.9% | |
| LTM Mar 2026 | $13.31M USD | +6.6% | — | 29.4% | |
| LTM Mar 2026 | $331.65K USD | -73.3% | — | — | |
| LTM Jun 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | €0 EUR | +100.0% | +2.4% | 0.0% | |
| Peer median (excluding NVAX) | — | +53.3% | -39.0% | 12.9% | |
Competitors are the stored peer set for NVAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.74B) | (657.94M) | (545.06M) | (187.5M) | 440.3M |
| Depreciation & Amortization | 12.66M | 29.05M | 41.23M | 48.5M | 27.61M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 183.63M | 130.3M | 85.36M | 48.15M | 36.02M |
| Change in Working Capital | 1.73B | (361.15M) | (376.84M) | 48.48M | (887.71M) |
| Accounts Receivables | (192.27M) | 249.17M | (274.44M) | 354.09M | 61.04M |
| Inventory | (600.33M) | (477.8M) | (74.46M) | 12.91M | (3.24M) |
| Accounts Payables | 600.33M | 913.4M | (378.81M) | (385.63M) | (322.57M) |
| Other Working Capital | 1.93B | (1.05B) | 350.87M | 67.11M | (622.94M) |
| Other Non-Cash Items | 136.79M | 443.8M | 81.35M | (44.89M) | 139.14M |
| Operating Cash Flow | 322.95M | (415.94M) | (713.97M) | (87.26M) | (244.64M) |
| Capital Expenditures | (57.49M) | (92.99M) | (58.81M) | (13.06M) | (5.56M) |
| Acquisitions (Net) | 57.49M | 0 | 0 | 192.64M | 0 |
| Purchases of Investments | (2.17M) | 0 | 0 | (825.59M) | (445.27M) |
| Sales of Investments | 159.81M | 0 | 0 | 443.55M | 353.74M |
| Other Investing Activities | (57.49M) | 0 | 0 | 0 | 18.83M |
| Investing Cash Flow | 100.15M | (92.99M) | (58.81M) | (204.04M) | (78.27M) |
| Debt Repayment | (127.91M) | 81.66M | (352.35M) | (3.99M) | 32.53M |
| Common Stock Issued | 564.86M | 249.23M | 360.24M | 263.27M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (4.8M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 24.76M | (5.9M) | (3.59M) | 1.31M | 0 |
| Financing Cash Flow | 461.71M | 324.99M | 4.47M | 260.58M | 27.74M |
| Effect of Forex Changes | (5.29M) | 4.52M | 3.27M | (7.8M) | 5.93M |
| Net Change in Cash | 879.52M | (179.41M) | (765.04M) | (38.52M) | (289.24M) |
| Free Cash Flow | 265.46M | (508.92M) | (772.77M) | (100.32M) | (250.2M) |
Novavax, Inc.
NASDAQ:NVAX
Intrinsic Alpha fair value
Locked
Current Price
$7.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.